Impaired brain insulin signalling in Parkinson's disease-Reference-Cited by-同舟云学术

Impaired brain insulin signalling in Parkinson's disease

Published:2021-09-13 Issue:1 Volume:48 Page:
ISSN:0305-1846
Container-title:Neuropathology and Applied Neurobiology
language:en
Short-container-title:Neuropathology Appl Neurobio

Author:

Bassil Fares¹²,Delamarre Anna¹²,Canron Marie‐Hélène¹²,Dutheil Nathalie¹²,Vital Anne¹²³,Négrier‐Leibreich Marie‐Laure¹²³,Bezard Erwan¹²^ORCID,Fernagut Pierre‐Olivier¹²⁴^ORCID,Meissner Wassilios G.¹²⁵⁶⁷^ORCID

Affiliation:

1. Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293 Bordeaux France

2. CNRS, Institut des Maladies Neurodégénératives, UMR 5293 Bordeaux France

3. Service d'Anatomie Pathologique, CHU de Bordeaux Bordeaux France

4. Université de Poitiers, INSERM UMR 1084, Laboratoire de Neurosciences Expérimentales et Cliniques Poitiers France

5. Service de Neurologie – Maladies Neurodégénératives, CHU de Bordeaux Bordeaux France

6. Department of Medicine University of Otago Christchurch New Zealand

7. New Zealand Brain Research Institute Christchurch New Zealand

Funder

Association France Parkinson

Fondation pour la Recherche Médicale

Publisher

Wiley

Subject

Physiology (medical),Neurology (clinical),Neurology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nan.12760

Reference63 articles.

1. -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies

2. 100 years of Lewy pathology

3. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?

4. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

5. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein tyrosine phosphatase receptor type O serves as a key regulator of insulin resistance-induced α-synuclein aggregation in Parkinson’s disease;Cellular and Molecular Life Sciences;2024-09-14

2. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?;Neuropharmacology;2024-08

3. Wird die Progression gebremst?;InFo Neurologie + Psychiatrie;2024-08

4. In Parkinson’s disease, affective and chronic fatigue syndrome symptoms are associated with neuronal damage markers;2024-05-21

5. Role of metabolic dysfunction and inflammation along the liver–brain axis in animal models with obesity-induced neurodegeneration;Neural Regeneration Research;2024-05-17